These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26376678)

  • 61. Ever-advancing chronic myeloid leukemia treatment.
    Kimura S; Ando T; Kojima K
    Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
    Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
    Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
    González Rosa V; Gutiérrez Nicolás F; Gavira Moreno R; Viña Romero MM; Moreno Carvajal MT; Gázquez Pérez R
    Farm Hosp; 2013; 37(6):434-40. PubMed ID: 24256006
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
    Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
    J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
    Wang R; Cong Y; Li C; Zhang C; Lin H
    Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
    Eghtedar A; Kantarjian H; Jabbour E; O'Brien S; Burton E; Garcia-Manero G; Verstovsek S; Ravandi F; Borthakur G; Konopleva M; Quintas-Cardama A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):477-84. PubMed ID: 23770156
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
    Wang YY; Zhao HG; Cui ZG; Li GL; Shi X; Xu H; Zhou Y; Zhao T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):356-63. PubMed ID: 25948185
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
    Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
    Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia.
    Ciarcia R; Damiano S; Puzio MV; Montagnaro S; Pagnini F; Pacilio C; Caparrotti G; Bellan C; Garofano T; Polito MS; Giordano A; Florio S
    J Cell Physiol; 2016 Mar; 231(3):680-7. PubMed ID: 26235483
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
    Klink AJ; Keating SJ; Brokars J; Feinberg B; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):149-157. PubMed ID: 38135632
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
    Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 79. [Current therapy of chronic myeloid leukemia].
    Koskela H; Koskenvesa P; Mustjoki S; Porkka K
    Duodecim; 2012; 128(6):579-88. PubMed ID: 22506320
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
    Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.